Therapeutic Focus

The MYOS Strategy

Our strategy is to understand the complex genetic and molecular pathways regulating muscle mass and function, as well as other disease mechanisms. Understanding the impact of complex regulatory pathways which act to build and maintain healthy lean muscle is central to our company’s pioneering biotherapeutic discovery science. This research is the foundation of our bionutritional product development. MYOS is developing nutritional products that target specific mechanisms to promote health in ways that cannot be met by other treatments, diets or lifestyle changes. 

Learn More

Clinical Trials and Pre-Clinical Studies

Effects of MYO-T12 on lean body mass, strength, and power in resistance trained males / 100%
Impact of MYO-T12 alone or in combination with Testosterone on Muscle Growth / 50%
Effects of MYO-T12 on blood chemistry and BMI in healthy adult females / 30%

Our Partners

RSS Investor Relations and News

  • MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer July 30, 2014
    Consumer Product Industry Expert Will Lead Creation of New Bionutrition Products Exploiting Muscle Building Activity of Fortetropin CEDAR KNOLLS, NJ -- (Marketwired) -- 07/30/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and [...]
  • MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin July 25, 2014
    Global Leader in Food Technology, DIL, Partners With MYOS CEDAR KNOLLS, NJ -- (Marketwired) -- 07/25/14 -- MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced [...]

Stock Snapshot

MYOS Symbol
NASDAQ Market
Market Cap
Price
Change
Volume